NeuroPace (NPCE) Investor Day 2025 summary

Strategic vision and growth initiatives

• Targeting over 20% CAGR revenue growth from 2025 to 2027, driven by market, indication, and site of service expansion, as well as new product launches and clinical trial submissions.

• Focused on becoming the standard of care for drug-resistant epilepsy, with plans to expand into generalized and pediatric epilepsy, leveraging the differentiated RNS System technology.

• Execution discipline emphasized through gross margin improvement, operating expense optimization, and leveraging commercial investments for broader reach.

• Care program and direct-to-consumer strategies are expanding access, with meaningful revenue impact and plans to double community center contributions.

• Long-term goal to achieve cash flow break-even by 2027, supported by scalable AI-driven tools and operational leverage.

Clinical and product development

• Post-approval study shows median seizure reduction of 82% at three years, with 42% of patients seizure-free for at least six months and nearly a quarter seizure-free for a year.

• Nautilus trial for idiopathic generalized epilepsy completed enrollment rapidly; FDA breakthrough designation granted, with primary endpoint data expected in 2025.

• Pediatric indication expansion pursued via real-world data collaboration with FDA and NESTcc, aiming for submission in the second half of 2025.

• AI-powered software tools, remote programming, and next-generation platform development are underway to enhance therapy effectiveness, clinic efficiency, and ease of use.

• Data-driven product pipeline includes automated seizure detection, personalized therapy settings, and remote patient management, supporting scalability and improved outcomes.

Market development and financial guidance

• 2025 revenue guidance set at $92–$96 million, with gross margin of 73–75% and operating expenses of $92–$95 million.

• Revenue growth in 2024 exceeded 20%, with over 25% growth when adjusted for trial-related sales; momentum expected to continue through expanded care centers and DTC efforts.

• Addressable market expected to double with expansion into generalized and pediatric epilepsy, supported by strong clinical data and physician education initiatives.

• Professional and patient education, digital marketing, and nurse navigator programs are key to driving adoption and supporting referral pathways.

• Replacement revenue cycle for next-gen devices is anticipated to contribute to future growth as earlier models reach end of life.